Clinical Trials Browser

Phase 1 × asparaginase erwinia chrysanthemi recombinant × Clear all

NCT07133997 2026-03-13

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Phase 1 Not yet recruiting

Burkitt Lymphoma

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Phase 1 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00928200 2019-02-19

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

Phase 1 Terminated

1 enrolled 7 charts

LymphoidOther hematologic neoplasm

Hypersensitivity, Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02283190 2018-03-12

1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02647190 2017-06-02

Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma